PHASE-XS is a proprietary database of Coherent Market Insights, which offers in-depth information about late-stage (phase 3 and later) biologics and biosimilar candidates. Developed by our team of consultants and industry experts, PHASE-XS aims to shed light on potential developments on such candidates.
One of the key aspects of PHASE-XS is offering easy understanding of, not just freely accessible clinical information (unlike provided by competitors), but also providing insights through a vast range of parameters outlined in the database. These include over 30 parameters which are profiled for each clinical trial. Phase-XS combines clinical and analytical insights on pipeline products under one umbrella.
A strong end point and trial design is critical for the success of late-stage biologics. PHASE-XS offers clinically essential information on pipeline products for the researchers with substantial R&D investments.
PHASE-XS provides key market related insights that can impact the respective therapeutic segments in terms of future competition, dynamics and trends.
Knowing your competitor activities and new product developments is an integral part of strategic discussions. PHASE-XS helps you know your competitor’s strengths, weakness, and potential with scrupulous insights from our team of industry experts.
User-friendly representation and deliverable is what we strive for our PHASE-XS subscribers. Coherent Market Insights offers this data in the format that enables a user to easily perform analytics/analysis and get the desired outcomes in just few seconds.
To request for sample data or to subscribe, kindly fill this form.